Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With Itacitinib (INCB039110) in Subjects With Relapsed or Refractory Hodgkin Lymphoma

NCT02456675 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02456675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02456675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With Itacitinib (INCB039110) in Subjects With Relapsed or Refractory Hodgkin Lymphoma
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2015
Completion date
December 16, 2016
Enrollment
8 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult hodgkin's lymphoma, refractory hodgkin lymphoma